In December, 1958, griseofulvin became available to the District of Columbia Health Department Ringworm Clinic for clinical investigation, and during the next eight months 153 children with tinea capitis were treated with the drug on an out-patient basis. These included 137 cases of Microsporum audouini infection, 8 cases of Trichophyton tonsurans infection, and 8 cases of Microsporum canis infection. Six of the T. tonsurans cases and five of the M. canis cases have previously been reported, as have preliminary data in eighty-one of the M. audouini cases.1 Final data in reference to 137 cases of M. audouini infection are summarized in Table 1. The only untoward reactions were in two cases, previously reported.
To summarize our experiences and impressions in brief, we found that although 20 of 29 patients treated for four weeks or less had become Wood's-light-negative and culture-negative by the 16th week of observation with only three recurrences in children apparently cured, our most consistent and predictable results were obtained by extending therapy until two weeks after the
JACQUELYN KIRK, VERLIN E. MILES. Use of Griseofulvin in the Therapy of Tinea Capitis in ChildrenII. Single Dose and Monthly Doses. AMA Arch Derm. 1960;81(5):807–812. doi:10.1001/archderm.1960.03730050163030